ApoB / ApoA1 Ratio

The ApoB/ApoA1 ratio is a blood marker that compares two key proteins involved in cholesterol transport: apolipoprotein B (ApoB) and apolipoprotein A1 (ApoA1). These proteins sit on the surface of cholesterol-carrying particles and determine how cholesterol behaves in the body. ApoB is found on all cholesterol particles that can contribute to plaque formation in arteries, including LDL (“bad cholesterol”), VLDL, and other atherogenic particles. Each of these particles carries exactly one ApoB molecule, meaning ApoB reflects the number of potentially harmful cholesterol particles, not just how much cholesterol they contain.

ApoA1, in contrast, is the main protein found on HDL (“good cholesterol”). HDL particles help remove excess cholesterol from the bloodstream and vessel walls and transport it back to the liver for recycling or elimination. ApoA1 therefore reflects the body’s protective capacity against cholesterol buildup.

The ApoB/ApoA1 ratio compares these opposing forces. A higher ratio means there are many more cholesterol particles capable of entering artery walls compared with protective HDL particles. A lower ratio indicates a healthier balance, with stronger cholesterol clearance relative to cholesterol delivery. This ratio often provides more accurate insight than LDL or HDL alone because it captures particle balance, not just cholesterol concentration.

The ApoB/ApoA1 ratio is one of the strongest predictors of cardiovascular disease, including heart attack and stroke. Research consistently shows that this ratio predicts risk more accurately than traditional cholesterol markers such as LDL-cholesterol or total cholesterol, particularly in people with insulin resistance, obesity, type 2 diabetes, or metabolic syndrome.

One reason this ratio is so powerful is that cardiovascular damage is driven by particle number, not cholesterol mass alone. Someone can have “normal” LDL-cholesterol but still have a high number of ApoB-containing particles, meaning more opportunities for cholesterol to enter artery walls. This explains why cardiovascular disease can develop even when standard cholesterol tests appear reassuring.

A high ApoB/ApoA1 ratio indicates a state where cholesterol delivery to tissues outweighs cholesterol removal. Over time, this imbalance increases the likelihood that ApoB-containing particles will penetrate the artery wall, become trapped, and trigger inflammation. This process leads to plaque formation (atherosclerosis), reduced blood flow, and increased risk of cardiovascular events.

The ratio is particularly useful in identifying hidden risk in younger individuals, those with a family history of early heart disease, or people with mixed lipid patterns (for example, normal LDL but low HDL or high triglycerides). Because ApoB/ApoA1 reflects both harmful and protective pathways, improving this ratio through diet, lifestyle, and targeted interventions is associated with meaningful reductions in long-term cardiovascular risk.

The INTERHEART study — a landmark trial of over 27,000 people across 52 countries — found that this ratio outperformed LDL-C, HDL-C, and total cholesterol as a predictor of myocardial infarction (heart attack). This study showed that every 0.1 increase in the ApoB/A1 ratio can raise your heart attack risk by ~20%. A ratio < 0.7 is ideal for most people; < 0.6 for those with heart disease or diabetes.

In short:

High ApoB / low ApoA1 = arterial overload. 

• More cholesterol is being delivered than cleared. 

Low ApoB / high ApoA1 = resilient arteries. 

• You’re efficiently removing cholesterol before it builds up.

This ratio reflects how effectively your body handles cholesterol transport and clearance, and it fluctuates with metabolic, dietary, and lifestyle factors.

Key influences include:

• High refined carbohydrate or sugar intake: raises triglycerides and ApoB.

• Low intake of healthy fats: reduces HDL and ApoA1.

• Low physical activity: reduces ApoA1 and raises ApoB.

• Visceral fat and insulin resistance: promote small, dense LDL particles (high ApoB).

• Smoking and chronic stress: impair HDL function and raise oxidative stress.

• Thyroid and liver health: hypothyroidism and fatty liver can both raise ApoB.

• Genetic factors: some individuals naturally overproduce ApoB or have reduced ApoA-I efficiency.

If your results are high

Your results are high, meaning there are more harmful cholesterol particles relative to protective ones.

Diet:

• Minimise processed foods and avoid trans fats.

• Limit added sugars and refined carbohydrates.

• Aim for 2–3 servings of fatty fish weekly (such as salmon or sardines).

• Include 10–25 g of soluble fibre daily from oats, beans, lentils, apples, and citrus.

• Use olive oil, nuts, and seeds in place of butter or margarine.

• Consider foods fortified with plant sterols/stanols (~2 g/day).
  .

Lifestyle:

• Accumulate at least 150 minutes of moderate exercise per week.

• Aim for gradual weight loss if overweight (5–10%).

• Avoid smoking and keep alcohol intake moderate.

Supplements:
Plant sterols/stanols, psyllium fibre, omega-3 fatty acids, or red yeast rice may be considered under healthcare supervision.

Additional tests:

• If the ratio is markedly elevated or there is a family history of early heart disease

• discuss further risk markers such as lipoprotein(a) or genetic lipid disorders with a healthcare provider.
  

If your results are low

Your results are low, indicating a favourable balance between protective and harmful cholesterol particles.

Diet:

• Continue a balanced, whole-food diet with healthy fats, lean proteins, and abundant fruits and vegetables.

• Avoid overly restrictive low-fat diets unless advised.
  .

Lifestyle:
Maintain regular physical activity and a healthy body weight.

Supplements:
No supplements are needed to raise the ratio.

Additional tests:

• If the ratio is extremely low and symptoms are present

• discuss with a healthcare provider

1. Wilson PWF, et al. Lipid Measurements in the Management of Cardiovascular Diseases. J Clin Lipidol. 2021;15(5):629-648.

2. Jacobson TA. Opening a New Lipid “Apo-Thecary”. Mayo Clin Proc. 2011;86(8):762-780.

3. Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022;43(4):611-653.

4. Sniderman A, et al. Update on Apolipoprotein B. Curr Opin Lipidol. 2021;32(4):226-230.

5. De Oliveira-Gomes D, et al. Apolipoprotein B: Bridging Evidence and Practice. Circulation. 2024;150(1):62-79.

6. Stone NJ, et al. Managing ASCVD Risk in Young Adults. J Am Coll Cardiol. 2022;79(8):819-836.

7. Cole J, et al. ApoB in Precision Medicine. J Clin Med. 2023;12(17):5737.

8. Bilgic S, Sniderman AD. ApoB for Cardiovascular Care. Curr Opin Cardiol. 2024;39(1):49-53.

9. Ruhaak L, et al. Apolipoprotein Profiling. Ann Clin Biochem. 2019;56(3):338-356.

10. Jacobson TA, et al. NLA Recommendations for Dyslipidemia. J Clin Lipidol. 2015;9(2):129-169.

11. Lamantia V, Sniderman A, Faraj M. Nutritional Management of HyperapoB. Nutr Res Rev. 2016;29(2):202-233.